021-51111890
购物车（）
sales@molnova.cn
Relacorilant
CAS No. 1496510-51-0
Relacorilant ( CORT 125134 )
产品货号. M23647 CAS No. 1496510-51-0
Relacorilant is a selective and orally bioavailable antagonist of glucocorticoid receptor.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2284 | 有现货 |
|
| 10MG | ￥3629 | 有现货 |
|
| 25MG | ￥6051 | 有现货 |
|
| 50MG | ￥8505 | 有现货 |
|
| 100MG | ￥11502 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Relacorilant
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Relacorilant is a selective and orally bioavailable antagonist of glucocorticoid receptor.
-
产品描述Relacorilant is a selective and orally bioavailable antagonist of glucocorticoid receptor(Ki of 7.2 nM in HepG2 TAT assay, and also shows Kis of 12, 81.2, 210 nM for rat, human and monkey glucocorticoid receptor in cell-based assay, respectively). Relacorilant has the potential for Cushing’s syndrome treatment.
-
同义词CORT 125134
-
通路Others
-
靶点Other Targets
-
受体Glucocorticoid receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number1496510-51-0
-
分子量586.6
-
分子式C27H22F4N6O3S
-
纯度>98% (HPLC)
-
溶解度DMSO:10 mM
-
SMILESCN1C=C(C=N1)S(=O)(=O)N2CCC3=CC4=C(C[C@@]3(C2)C(=O)C5=NC=CC(=C5)C(F)(F)F)C=NN4C6=CC=C(C=C6)F
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Hunt HJ, et al. Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist. J Med Chem. 2017 Apr 27;60(8):3405-3421.
产品手册
关联产品
-
TAPI 2
ADAM-17 (TACE) and MMP inhibitor (Ki = 120 nM at ADAM-17). Sensitizes cancer stem cells to the lethal effects of 5-FU in vitro. Blocks shedding of TNF-α from cell membranes.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Beta-Sitosterol
β-Sitosterol has recently been shown to induce G2/M arrest, endoreduplication, and apoptosis through the Bcl-2 and PI3K/Akt signaling pathways.
